| Budget Amount *help |
¥173,030,000 (Direct Cost: ¥133,100,000、Indirect Cost: ¥39,930,000)
Fiscal Year 2020: ¥30,680,000 (Direct Cost: ¥23,600,000、Indirect Cost: ¥7,080,000)
Fiscal Year 2019: ¥45,500,000 (Direct Cost: ¥35,000,000、Indirect Cost: ¥10,500,000)
Fiscal Year 2018: ¥41,340,000 (Direct Cost: ¥31,800,000、Indirect Cost: ¥9,540,000)
Fiscal Year 2017: ¥38,480,000 (Direct Cost: ¥29,600,000、Indirect Cost: ¥8,880,000)
Fiscal Year 2016: ¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study was to develop a new biomaterial that can stably deliver and controlled release biopharmacy. We designed a novel functional self-assembled nanogel by using amphipathic polysaccharides as DDS for proteins, nucleic acids and exosomes. We also found a new polymer vesicle with substance permeability. It was clarified that the enzyme-encapsulated polymer vesicle can function as a DDS nanofactory. We found that a nanogel / magnetic nanoparticle hybrid showed a new magnetically controlled protein delivery system. In the application of cancer treatment, we proposed a function control technology for tumor-related macrophages using hydrophobic polysaccharide nanogels.In the application of regenerative medicine, we established a method of nanogel tectonics using nanogel as a constituent unit (tecton), and clarified that nanogel-crosslinked porous gel is excellent as an artificial extracellular matrix for bone regenerative cell therapy.
|
